Many machines are required for pharmaceutical milling processes. Can you reduce that number, streamline operations and improve efficiency?

A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.

One company is determined to improve drug development success rates, and its cell simulation platform is already being used ...

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.

Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.

Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.

J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

Fate has announced the retirement of president and CEO Scott Wolchko with Bob Valamehr set to assume the role from 1 January ...

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.